The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.

Following a positive meeting with the FDA, BrainChild is getting ready to initiate a pivotal registration trial with its lead ...

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...